PFS
Fig. 1 · Panel 12-month_PFS
Panel 12-month_PFS 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kazutaka Sunami, Hiroshi Handa, Michiko Ichii, Takayuki Ikezoe, Kazuhito Suzuki, Yusuke Yamaguchi, Taeko Yonekawa, Akira Endo, Hirofumi Nakano, Eric Lewis, Ianire Garrobo Calleja, Elisabet Manasanch, Shigeki Ito, Hitomi Kato
Int J Hematol 123(5) 686-695
The phase 3 DREAMM-8 (NCT04484623) trial assessed belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs bortezomib + Pd (PVd) in lenalidomide-exposed patients with relapsed/refractory multiple myeloma (RRMM) and ≥ 1 prior therapy. Here, we present findings from Japanese patients (data cutoff: 27-May-24). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), duration of response (DoR), and safety. Overall, 21 patients were randomized 1:1 to BPd (N = 10) and PVd (N = 11). Median follow-up was 13.8 months (range 0.23-26.71). For BPd vs PVd, median PFS was not reached (NR; 95% CI 0.2-NR) vs 14.8 months (95% CI 1.9-NR; HR 0.53; 95% CI 0.1-2.8); ORR was 90% (9/10) vs 73% (8/11), including very good partial response or better in 70% (7/10) vs 36% (4/11); median DoR was NR vs 17.5 months. The safety profile was consistent with the global cohort. Ocular adverse events were more common with BPd vs PVd (90% [9/10] vs 9% [1/11]) and a majority were transient and reversible. While the sample size of this study is small, findings were aligned with the global cohort. BPd showed favorable efficacy compared with PVd, with a manageable safety profile in lenalidomide-exposed Japanese patients with RRMM.
1 个 Figure · 1 个 KM 面板
Fig. 1 Kaplan–Meier Analysis of Progression-free Survival. BPd, belantamab mafodotin, pomalidomide, and dexamethasone; PFS, progression-free survival; PVd, pomalidomide, bortezomib, and dexamethasone; NR, not reached
Fig. 1 · Panel 12-month_PFS
Panel 12-month_PFS 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。